- Fully executed exclusive sales agreement descibing product IP, conveyance method, price/terms, payment method,
non-disclosure conditions, identities of parties to the contract, and
other conditions.
- Drug prospectus descibing in-silico
drug performance compared to experimentally-verified and/or
FDA-approved drugs that compete for the same target receptor(s). The
prospectus provides a summary of drug docking results, drug-target
complex stability computed by MD simulations in physiological saline,
and an extensive ADMET profile, including synthetic accessibility.
- All supporting raw data used to generate the performance prospectus, including MD trajectories in GROMACS XTC, AMBER MDCrd, Yasara SIM, or simply PDB format.
- Complete description of methods and strategies employed to generate the IP.
- Molecular structure of the drug including its calculated electronic properties (orbital energies, electron distribution, and so forth.
- Up to 8 hours of consulting services
provided at 50% of our normal rate in support of IP transitioning (e.g., for further
target optimization or refinement, similarity searches over large
chemical space, etc.)
- Additional unlimited consulting services made available at our normal competitive rate to provide further detailed computational studies of the compound.
|
Important Note: The
drug structure is not disclosed in the prospectus, only comparative
performance results. The drug strucure and all raw supporting data will
be exclusively released to the buyer following confirmation of
payment recieved.
